UAB The University of Alabama at Birmingham

The UAB Institutional Biosafety Committee Meeting Minutes
Research Involving Recombinant and Synthetic Nucleic Acid Molecules
October 13, 2026, 10:00 am

Members	Present (Y/N)	Vote (Y/N)
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Aftab Ahmad, PhD, Lab Rep [AA]	N	N
3. Julie Allen, DNP, Occupational Medicine [JSA]	Y	Y
4. Cameron Crosby, MD, Occupational Medicine [JCC]	N	N
5. Qiang (John) Ding, PhD, Veterans' Affairs [QJD]	N	N
6. Chad Dunaway, IACUC [CD]	Y	Y
7. Lillie Flood, RN-BSN, JCDH, Community Member [LF]	Y	Y
8. Julie Gray, BS, EHS [JDG]	N	N
9. Kevin Harrod, PhD, Lab Rep [KH]	N	N
10. Rebecca Johnstone, Recording Secretary [RMJ]	N	N
11. Masakazu Kamata, PhD, Lab Rep [MK]	N	N
12. Brian Lagory, BS, Biosafety Officer [BEL]	Y	Y
13. Adam McClintock, MBA, HRPP [AM]	N	N
14. Andrea Osborne, DVM, ARP [AJO]	Y	Y
15. Larisa Pereboeva, PhD, Lab Rep [LP]	N	N
16. Vineel Reddy, PhD, Biosafety Officer [VPR]	Y	Y
17. Justin Roth, PhD, EHS [JCR]	Y	N
18. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	Y
19. Theresa Strong, PhD, Lab Rep [TVS]	N	N
20. Tyler Uzzell, MA, HRPP [TWU]	Y	Y
21. Amanda J. Watts, MS, IACUC [AJW]	N	N
22. Wesley Willeford, MD, JCDH, Community Member [WW]	N	N
23. Donna Williamson, MS, RSS [DSW]	N	N
24. Christine M. Wright, PhD, Lab Rep [CMW]	Y	Y
Total	11	10

Guests Present

Susan Pelmer, RSS [SP]

The October 13, 2026, Institutional Biosafety Committee (IBC) meeting for research involving recombinant or synthetic nucleic acid molecules was called to order at 10:04 a.m. via web-based video conferencing tool by the Chair. A quorum was present.

Project Review – The review and discussion of projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.

Adjournment

The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 10:12 am.

Respectfully submitted by:

04 November 2026

Amanda F. Smith Date
Associate Director, RSS

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Not Approve	Abstain or Recuse	RSC #	Evaluation
10	--	--	14-240	**(III.D.4.b) Gu, Jianguo; Mechanisms of Nociception in the Trigeminal System** **Reason for IBC:** • Administration of recombinant AAV vectors expressing shRNA constructs to animals **Containment Requirements:** • BSL-1 practices and procedures may be used for handling of AAV. • ABSL-2 practices and procedures, including the posting of an AUSI, will be used for 14 days after the last AAV administration, the ABSL-1 may be used.
10	--	--	25-192	(**III.D.4.b) Volpicelli-Daley, Laura; Inhibition of Acid Ceramidase as a Therapy for GBA1-associated PD** **Reason for IBC:** • Administration of recombinant AAV vectors expressing human a-syn and GFP to animals **Containment Requirements:** • BSL-1 practices and procedures may be used for handling of AAV. • ABSL-2 practices and procedures, including the posting of an AUSI, will be used for 14 days after the last AAV administration, the ABSL-1 may be used.